An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer

Trial Profile

An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Anthracyclines; Taxanes
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BEATRICE
  • Sponsors Roche
  • Most Recent Events

    • 15 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Nov 2014 The trial status is given as completed in UKCRN,and as active, no longer recruiting in NCT; retained as per NCT because it includes more locations than UKCRN.
    • 13 Dec 2013 Results of an analysis for patients who received radiotherapy (n=84) presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top